The Melanoma Letter Summer 2015, Vol. 33, No. 1

Our lead story in this issue of The Melanoma Letter, by Drs. Charles Balch, Mark Faries, and John Thompson, presents an authoritative and detailed review of SLNB in melanoma, with special attention to the results of MSLT-1. Our second story, by Dr. Jean-Jacques Grob, explores the questions remaining about the efficacy of SLNB, reviews the German data on completion LND, and looks forward to an era of increasingly precise staging/prognostication based on molecular studies of the primary tumors and blood. These two complementary stories provide a fairly comprehensive update and perspective on this important subject.